These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 18446503)

  • 1. Informatic tools and approaches in postmarketing pharmacovigilance used by FDA.
    Weaver J; Willy M; Avigan M
    AAPS J; 2008; 10(1):35-41. PubMed ID: 18446503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA post-marketing safety decisions.
    Klein DF
    J Clin Psychiatry; 2006 Aug; 67(8):1305-6. PubMed ID: 16965212
    [No Abstract]   [Full Text] [Related]  

  • 3. Application of FDA adverse event report data to the surveillance of dietary botanical supplements.
    Wallace RB; Gryzlak BM; Zimmerman MB; Nisly NL
    Ann Pharmacother; 2008 May; 42(5):653-60. PubMed ID: 18397972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
    Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
    Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA seeks advice on track-and-trace systems.
    Traynor K
    Am J Health Syst Pharm; 2011 Apr; 68(7):552-4. PubMed ID: 21411794
    [No Abstract]   [Full Text] [Related]  

  • 6. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 7. Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project.
    McKoy JM; Fisher MJ; Courtney DM; Raisch DW; Edwards BJ; Scheetz MH; Belknap SM; Trifilio SM; Samaras AT; Liebling DB; Nardone B; Tulas KM; West DP
    Drug Saf; 2013 May; 36(5):335-47. PubMed ID: 23553448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
    Fed Regist; 1993 Jun; 58(105):31596-614. PubMed ID: 10171452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What's next after 50 years of psychiatric drug development: an FDA perspective.
    Laughren TP
    J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signal detection methodologies to support effective safety management.
    van Manen RP; Fram D; DuMouchel W
    Expert Opin Drug Saf; 2007 Jul; 6(4):451-64. PubMed ID: 17688389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Data Sources That Support US Food and Drug Administration Medical Devices Safety Communications.
    Tau N; Shepshelovich D
    JAMA Intern Med; 2020 Nov; 180(11):1420-1426. PubMed ID: 32986074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
    Beninger P; Murray M
    Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A quantitative analysis of adverse events and "overwarning" in drug labeling.
    Duke J; Friedlin J; Ryan P
    Arch Intern Med; 2011 May; 171(10):944-6. PubMed ID: 21606101
    [No Abstract]   [Full Text] [Related]  

  • 14. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
    Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems.
    Raschi E; Girardi A; Poluzzi E; Forcesi E; Menniti-Ippolito F; Mazzanti G; De Ponti F
    Drug Saf; 2018 Aug; 41(8):745-752. PubMed ID: 29582393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health.
    Ronquillo JG; Zuckerman DM
    Milbank Q; 2017 Sep; 95(3):535-553. PubMed ID: 28895231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 18. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.
    Ball R; Robb M; Anderson SA; Dal Pan G
    Clin Pharmacol Ther; 2016 Mar; 99(3):265-8. PubMed ID: 26667601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.
    Botelho SF; Martins MA; Vieira LB; Reis AM
    J Clin Pharmacol; 2017 Apr; 57(4):493-499. PubMed ID: 27568487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS).
    Hoffman KB; Demakas AR; Dimbil M; Tatonetti NP; Erdman CB
    Drug Saf; 2014 Nov; 37(11):971-80. PubMed ID: 25255848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.